KR940009168A - Novel Jerry Cudranin Compound and Method for Making the Same - Google Patents

Novel Jerry Cudranin Compound and Method for Making the Same Download PDF

Info

Publication number
KR940009168A
KR940009168A KR1019920018255A KR920018255A KR940009168A KR 940009168 A KR940009168 A KR 940009168A KR 1019920018255 A KR1019920018255 A KR 1019920018255A KR 920018255 A KR920018255 A KR 920018255A KR 940009168 A KR940009168 A KR 940009168A
Authority
KR
South Korea
Prior art keywords
pharmaceutically acceptable
jerrykudranin
derivative
compound
acceptable salt
Prior art date
Application number
KR1019920018255A
Other languages
Korean (ko)
Other versions
KR100197866B1 (en
Inventor
유익동
김창진
이인경
김환묵
오구택
Original Assignee
서정욱
한국과학기술연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 서정욱, 한국과학기술연구원 filed Critical 서정욱
Priority to KR1019920018255A priority Critical patent/KR100197866B1/en
Publication of KR940009168A publication Critical patent/KR940009168A/en
Application granted granted Critical
Publication of KR100197866B1 publication Critical patent/KR100197866B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/40—Separation, e.g. from natural material; Purification

Abstract

본 발명은 항균 및 항암활성을 갖는 하기 구조식(1), (2) 및 (3)의 제리쿠드라닌 화합물 및 제리쿠드라닌 성분을 함유하는 식물체로부터 상기 화합물을 제조하는 방법에 관한 것이다.The present invention relates to a method for producing the compound from a plant containing the gerikudranin compound and the gerikudranin component of the following structural formulas (1), (2) and (3) having antibacterial and anticancer activity.

Description

신규의 제리쿠드라닌 화합물 및 그의 제조방법Novel Jerry Cudranin Compound and Method for Making the Same

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

제1도는 제리쿠드라닌 에이(gericudranin A)의 자외선 흡수 스펙트럼,1 is the ultraviolet absorption spectrum of gericudranin A,

제2도는 제리쿠드라닌 에이(gericudranin A)의 적외선 흡수 스펙트럼,2 shows the infrared absorption spectrum of gericudranin A,

제3도는 제리쿠드라닌 에이(gericudranin A)의 수소핵자기 공명 스펙트럼,3 shows the hydrogen nuclear magnetic resonance spectrum of gericudranin A,

제4도는 제리쿠드라닌 에이(gericudranin A)의 탄소핵자기 공명 스펙트럼.4 is the carbon nuclear magnetic resonance spectrum of gericudranin A.

Claims (5)

항균 및 항암활성을 갖는 다음 구조식(1)의 제리쿠드라닌 에이, 그의 유도체 및 약학적으로 허용가능한 그의 염.Jerrykudranin A, a derivative thereof, and a pharmaceutically acceptable salt thereof, having the following antibacterial and anticancer activity: 항균 및 항암활성을 갖는 다음 구조식(2)의 제리쿠드라닌 에이, 그의 유도체 및 약학적으로 허용가능한 그의 염.Jerrykudranin A, a derivative thereof, and a pharmaceutically acceptable salt thereof, having the following antibacterial and anticancer activity: 항균 및 항암활성을 갖는 다음 구조식(3)의 제리쿠드라닌 씨, 그의 유도체 및 약학적으로 허용가능한 그의 염.Jerrykudranin seed of the following formula (3) having antibacterial and anticancer activity, derivatives thereof and pharmaceutically acceptable salts thereof. (1)제리쿠드라닌 활성물질을 함유하는 식물체를 메탄올 용액으로 추출하여 활성물질을 추출하고, (2)추출액을 농축시킨 후 다시 클로로포름으로 추출하며, (3)물층을 에틸 아세테이트로 3회 추출한 후 에틸아세테이트층을 클로로포름/메탄올로 실리카겔 컬럼 크로마토그래피를 2회 반복 실시하여 활성분획물을 수득하고, (4)상기 활성분획물을 오디에서(ODS)역상 컬럼을 이용하여 크로마토그래피함을 포함하는 제1항 내지 3항중 어느 한 항의 제리쿠드라닌을 제조하는 방법.(1) extracting the active substance containing the active substance of zericudanin with methanol solution to extract the active substance, (2) extract the concentrated solution and extracted again with chloroform, and (3) water layer extracted three times with ethyl acetate The ethyl acetate layer was then repeatedly subjected to silica gel column chromatography with chloroform / methanol twice to obtain an active fraction, and (4) the active fraction was chromatographed using an ODS inverse phase column. A method for producing the zericudranine of any one of claims 3 to 4. 제1항 내지 제3항중 어느 한 항의 제리쿠드라닌, 그의 유도체 및 약학적으로 허용가능한 그의 염중 적어도 하나를 유효성분으로 포함하는 항균 및 항암 조성물.An antimicrobial and anticancer composition comprising as an active ingredient at least one of jerrycutranine, a derivative thereof and a pharmaceutically acceptable salt thereof according to any one of claims 1 to 3. ※참고사항:최초출원 내용에 의하여 공개하는 것임.※ Note: This is to be disclosed based on the first application.
KR1019920018255A 1992-10-06 1992-10-06 Novel gericudranin compounds and process for their preparations KR100197866B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019920018255A KR100197866B1 (en) 1992-10-06 1992-10-06 Novel gericudranin compounds and process for their preparations

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019920018255A KR100197866B1 (en) 1992-10-06 1992-10-06 Novel gericudranin compounds and process for their preparations

Publications (2)

Publication Number Publication Date
KR940009168A true KR940009168A (en) 1994-05-20
KR100197866B1 KR100197866B1 (en) 1999-06-15

Family

ID=19340636

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019920018255A KR100197866B1 (en) 1992-10-06 1992-10-06 Novel gericudranin compounds and process for their preparations

Country Status (1)

Country Link
KR (1) KR100197866B1 (en)

Also Published As

Publication number Publication date
KR100197866B1 (en) 1999-06-15

Similar Documents

Publication Publication Date Title
YAMAZAKI et al. Tremorgenic toxins from Aspergillus fumigatus Fres
Omura et al. Pyripyropenes, highly potent inhibitors of acyl-CoA: cholesterol acyltransferase produced by Aspergillus fumigatus
KR940001886A (en) Pharmaceutical preparations that inhibit the replication of hepatitis B virus (HBV)
KR950010877A (en) External skin preparation
ES8103088A1 (en) Spiro-(dihydrobenzofuranpiperidines and -pyrrolidines) and derivatives thereof, methods for their preparation and medicines containing them.
DE3564566D1 (en) Quinone derivatives, method and use of preparing same, and pharmaceutical composition
Asakawa et al. Biotransformation of monoterpenoids,(−)-and menthols, terpinolene and carvotanacetone by Aspergillus species
ES2108129T3 (en) NEW DERIVATIVES OF PIRAZINE, ITS PREPARATION AND USE.
US5045533A (en) Retinoic esters of antibiotics and pharmaceutical and cosmetic compositions containing them
Pinto et al. Xanthone and antifungal constituents from Monnina obtusifolia
MX9501622A (en) Milbemycin derivatives having a substituent containing an oxime group at the 13-position.
KR940009168A (en) Novel Jerry Cudranin Compound and Method for Making the Same
KR880011168A (en) Process for preparing macrocyclic compound
Kjaer et al. Isothiocyanates XLIII. Isothiocyanates from Putranjiva roxburghii Wall. including (S)-2-methylbutyl isothiocyanate, a new mustard oil of natural derivation
KR890008156A (en) Novel alcoholic derivatives of gingkolide, preparation method thereof and therapeutic composition containing the same
KR900004939A (en) Method of preparation by microorganisms of agrochemically useful active ingredients
JPS5536403A (en) Preparation of 1-benzazonine derivative
KR970069973A (en) A new sesquiterpene ester compound
KR970009802A (en) Method of preparing a pharmaceutical extract from the preparation and a pharmaceutical composition for the prevention and treatment of liver disease containing the extract
JPS55111469A (en) Novel geldanamycin derivative, its preparation, and antitumor drug comprising it as active ingredient
JPS5655397A (en) Aminobenzoic acid ester derivative, and physiologically active agent containing said derivative
KR970027037A (en) Acylic-Coei: A method for preparing cholesterol acyltransferase (ACAT) inhibitor from foliar leaves
DK455487D0 (en) 13ALFA-ALKYLGONAN-DELTA9 (11) -5,10-EPOXIDES AND PROCEDURES FOR PREPARING THEREOF
C. Pinto et al. Absolute configuration of four cleistanthane diterpenes from Velloziaceae
KR960000917A (en) Polyoxypregnan Glycosides with Multiple Drug Resistance Regulation of Cancer Cells Extracted from Baek Shou

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20050119

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee